RxDoctor Payments Data

Raymond Hawkins, MD

General Practice · Somerville, TNNPI 1184622037

Payments from drug & device makers

$1,005in general payments, 2019–2025

Across 46 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$184
  • Johnson & Johnson$169
  • Nestle Healthcare Nutrition Inc.$153
  • Lilly USA, LLC$106
  • Astellas Pharma US Inc$59
  • Dexcom, Inc.$55
  • plus $278 from 9 others

What the payments were for

  • Food & beverage$1,005100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,005 in reported general payments places this provider in the 75th percentile of 1,632 general practice providers in Tennessee.

See all general practice providers in Tennessee

Medicare billing

Part B allowed, 2024
$147,726
Medicare patients
491
Services billed
2,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban240$48,753
XifaxanRifaximin46$40,671
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$31,393
JardianceEmpagliflozin43$28,864
MounjaroTirzepatide26$26,962
OzempicSemaglutide22$21,026
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$15,397
Janumet XrSitagliptin Phos/Metformin Hcl16$11,133
XareltoRivaroxaban69$10,824
NuedextaDextromethorphan Hbr/Quinidine19$9,896
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$9,392
FarxigaDapagliflozin Propanediol13$9,309
BrilintaTicagrelor42$7,967
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$6,040
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$41$40,78558 claims
AstraZenecaBreztri Aerosphere, Farxiga, Brilinta$184$32,67276 claims
Lilly USA, LLCMounjaro$106$26,96226 claims
Novo NordiskOzempic$34$21,02622 claims
Johnson & JohnsonXarelto$169$10,82469 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,632 general practice providers in Tennessee.

Other general practice in Somerville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →